Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/10.3322/caac.20107
   PubMed Web of Science ®Google Scholar
• Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14:535-46; PMID:25056707; http://dx.doi.org/10.1038/nrc3775
   PubMed Web of Science ®Google Scholar
• Yang L, Ren B, Li H, Yu J, Cao S, Hao X, Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2013; 62:65-73; PMID:22744010; http://dx.doi.org/10.1007/s00262-012-1311-8
   PubMed Web of Science ®Google Scholar
• Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med 2014; 7:1403-7; PMID:24940447
   PubMed Web of Science ®Google Scholar
• Pisters KM. Adjuvant chemotherapy for non-small-cell lung cancer-the smoke clears. N Engl J Med 2005; 352:2640-2; PMID:15972872; http://dx.doi.org/10.1056/NEJMe058110
   PubMed Web of Science ®Google Scholar
• Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, Brooks BJ, Perry MC, Livingston RB, Johnson DH. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. Eastern cooperative oncology group. N Engl J Med 2000; 343:1217-22; PMID:11071672; http://dx.doi.org/10.1056/NEJM200010263431703
   PubMed Web of Science ®Google Scholar
• Felip E, Martinez-Marti A, Martinez P, Cedres S, Navarro A. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments. Curr Opin Oncol 2013; 25:115-20; PMID:23262832; http://dx.doi.org/10.1097/CCO.0b013e32835ca1b0
   PubMed Web of Science ®Google Scholar
• Aerts JG, Hegmans JP. Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with Lung Cancer. Cancer Res 2013; 73:2381-8; PMID:23580578; http://dx.doi.org/10.1158/0008-5472.CAN-12-3932
   PubMed Web of Science ®Google Scholar
• Lv M, Xu Y, Tang R, Ren J, Shen S, Chen Y, Liu B, Hou Y, Wang T. miR-141-CXCL1-CXCR2 signaling-induced Treg cells recruitment regulates metastases and survival of non-small cell lung cancer. Mol Cancer Ther 2014; 13:3152-62; PMID:25349304; http://dx.doi.org/10.1158/1535-7163.MCT-14-0448
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366:2443-54; PMID:22658127; http://dx.doi.org/10.1056/NEJMoa1200690
   PubMed Web of Science ®Google Scholar
• Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012; 13:e301-10; PMID:22748269; http://dx.doi.org/10.1016/S1470-2045(12)70126-2
   PubMed Web of Science ®Google Scholar
• Hasegawa T, Suzuki H, Yamaura T, Muto S, Okabe N, Osugi J, Hoshino M, Higuchi M, Ise K, Gotoh M. Prognostic value of peripheral and local forkhead box P3 regulatory T cells in patients with non-small-cell lung cancer. Mol Clin Oncol 2014; 2:685-94; PMID:25054031; http://dx.doi.org/10.3892/mco.2014.299
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 2003; 3:666-75; PMID:12951585; http://dx.doi.org/10.1038/nrc1167
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90:51-81; PMID:16730261; http://dx.doi.org/10.1016/S0065-2776(06)90002-9
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang B, Gao H, Ding G, Wu Q, Zhang J, Liao L, Chen H. Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. Bmc Cancer 2014; 14:251; PMID:24720900; http://dx.doi.org/10.1186/1471-2407-14-251
   PubMed Web of Science ®Google Scholar
• Li JJ, Gu MF, Pan K, Liu LZ, Zhang H, Shen WX, Xia JC. Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother 2012; 35:189-95; PMID:22306907; http://dx.doi.org/10.1097/CJI.0b013e318241d9de
   PubMed Web of Science ®Google Scholar
• Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, Weng DS, Wang QJ, Liu Q, Huang LX et al. Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer. Clin Cancer Res 2014; 20:3003-11; PMID:24668644; http://dx.doi.org/10.1158/1078-0432.CCR-14-0082
   PubMed Web of Science ®Google Scholar
• Pan K, Li Y, Wang W, Xu L, Zhang Y, Zheng H, Zhao J, Qiu H, Weng D, Li J et al. The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Ann Surg Oncol 2013; 20:4305-11; PMID:23892527; http://dx.doi.org/10.1245/s10434-013-3144-x
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 2007; 7:329-39; PMID:17438573; http://dx.doi.org/10.1038/nri2073
   PubMed Web of Science ®Google Scholar
• Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008; 28:3997-4002; PMID:19192663
   PubMed Web of Science ®Google Scholar
• Zhong R, Han B, Zhong H. A prospective study of the efficacy of a combination of autologous dendritic cells, cytokine-induced killer cells, and chemotherapy in advanced non-small cell lung cancer patients. Tumor Biol 2014; 35:987-94; PMID:24006222; http://dx.doi.org/10.1007/s13277-013-1132-1
   PubMed Web of Science ®Google Scholar
• Li R, Wang C, Liu L, Du C, Cao S, Yu J, Wang SE, Hao X, Ren X, Li H. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012; 61:2125-33; PMID:22581306; http://dx.doi.org/10.1007/s00262-012-1260-2
   PubMed Web of Science ®Google Scholar
• Zhong R, Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011; 60:1497-502; PMID:21681372; http://dx.doi.org/10.1007/s00262-011-1060-0
   PubMed Web of Science ®Google Scholar
• Han RX, Liu X, Pan P, Jia YJ, Yu JC. Effectiveness and safety of chemotherapy combined with dendritic cells co-cultured with cytokine-induced killer cells in the treatment of advanced non-small-cell lung cancer: a systematic review and meta-analysis. PLoS One 2014; 9:e108958; PMID:25268709; http://dx.doi.org/10.1371/journal.pone.0108958
   PubMedGoogle Scholar
• Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo DL, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 2012; 12:673-84; PMID:22500889; http://dx.doi.org/10.1517/14712598.2012.675323
   PubMed Web of Science ®Google Scholar
• Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012; 12:565-72; PMID:22444075; http://dx.doi.org/10.1517/14712598.2012.668879
   PubMed Web of Science ®Google Scholar
• Hui KM. CIK cells-current status, clinical perspectives and future prospects-the good news. Expert Opin Biol Ther 2012; 12:659-61; PMID:22500927; http://dx.doi.org/10.1517/14712598.2012.676037
   PubMed Web of Science ®Google Scholar
• Ma Y, Zhang Z, Tang L, Xu YC, Xie ZM, Gu XF, Wang HX. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012; 14:483-93; PMID:22277010; http://dx.doi.org/10.3109/14653249.2011.649185
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-44; PMID:2201309; http://dx.doi.org/10.1016/0167-5699(90)90097-S
   PubMedGoogle Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21:1673-9; PMID:7694868
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 2002; 116:78-86; PMID:11841399; http://dx.doi.org/10.1046/j.1365-2141.2002.03247.x
   PubMed Web of Science ®Google Scholar
• Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI. Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood 2010; 116:1726-33; PMID:20519625; http://dx.doi.org/10.1182/blood-2009-07-234211
   PubMed Web of Science ®Google Scholar
• Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H, Li W. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014; 134:342-51; PMID:23825037; http://dx.doi.org/10.1002/ijc.28372
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
   PubMed Web of Science ®Google Scholar
• Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92:3318-27; PMID:9787169
   PubMed Web of Science ®Google Scholar
• Zhang YS, Yuan FJ, Jia GF, Zhang JF, Hu LY, Huang L, Wang J, Dai ZQ. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005; 11:3339-45; PMID:15948236; http://dx.doi.org/10.3748/wjg.v11.i22.3339
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta BA, Tsuruo T, Huhn D, Negrin RS. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996; 169:85-90; PMID:8612299; http://dx.doi.org/10.1006/cimm.1996.0094
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Leuci V, Todorovic M, Mesiano G, Picciotto F, Pisacane A, Zaccagna A, Volpe MG, Gallo S et al. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin Cancer Res 2013; 19:4347-58; PMID:23794732; http://dx.doi.org/10.1158/1078-0432.CCR-13-0061
   PubMed Web of Science ®Google Scholar
• Wu WC, Sun HW, Chen HT, Liang J, Yu XJ, Wu C, Wang Z, Zheng L. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A 2014; 111:4221-6; PMID:24591638; http://dx.doi.org/10.1073/pnas.1320753111
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106:u124; PMID:24875653; http://dx.doi.org/10.1093/jnci/dju124
   PubMedGoogle Scholar
• Kozlowska E, Biernacka M, Ciechomska M, Drela N. Age-related changes in the occurrence and characteristics of thymic CD4(+) CD25(+) T cells in mice. Immunology 2007; 122:445-53; PMID:17627771; http://dx.doi.org/10.1111/j.1365-2567.2007.02667.x
   PubMed Web of Science ®Google Scholar
• Muller L, Pawelec G. Aging and immunity - impact of behavioral intervention. Brain Behav Immun 2014; 39:8-22; PMID:24315935; http://dx.doi.org/10.1016/j.bbi.2013.11.015
   PubMed Web of Science ®Google Scholar
• Albright JW, Bream JH, Bere EW, Young HA, Winkler-Pickett R, Ortaldo JR. Aging of innate immunity: functional comparisons of NK/LAK cells obtained from bulk cultures of young and aged mouse spleen cells in high concentrations of interleukin-2. Exp Gerontol 2004; 39:73-82; PMID:14724067; http://dx.doi.org/10.1016/j.exger.2003.09.017
   PubMed Web of Science ®Google Scholar
• Schreiber K, Arina A, Engels B, Spiotto MT, Sidney J, Sette A, Karrison TG, Weichselbaum RR, Rowley DA, Schreiber H. Spleen cells from young but not old immunized mice eradicate large established cancers. Clin Cancer Res 2012; 18:2526-33; PMID:22415314; http://dx.doi.org/10.1158/1078-0432.CCR-12-0127
   PubMed Web of Science ®Google Scholar
• Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 2003; 9:2440-6; PMID:12855616
   PubMed Web of Science ®Google Scholar
• Carson WE, Parihar R, Lindemann MJ, Personeni N, Dierksheide J, Meropol NJ, Baselga J, Caligiuri MA. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001; 31:3016-25; PMID:11592078; http://dx.doi.org/10.1002/1521-4141(2001010)31:10%3c3016::AID-IMMU3016%3e3.0.CO;2-J
   PubMed Web of Science ®Google Scholar
• Parihar R, Dierksheide J, Hu Y, Carson WE. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells. J Clin Invest 2002; 110:983-92; PMID:12370276; http://dx.doi.org/10.1172/JCI0215950
   PubMed Web of Science ®Google Scholar